Literature DB >> 27979692

Therapeutic potential and limitations of cholinergic anti-inflammatory pathway in sepsis.

Alexandre Kanashiro1, Fabiane Sônego2, Raphael G Ferreira3, Fernanda V S Castanheira3, Caio A Leite3, Vanessa F Borges3, Daniele C Nascimento3, David F Cólon4, José Carlos Alves-Filho3, Luis Ulloa5, Fernando Q Cunha3.   

Abstract

Sepsis is one of the main causes of mortality in hospitalized patients. Despite the recent technical advances and the development of novel generation of antibiotics, severe sepsis remains a major clinical and scientific challenge in modern medicine. Unsuccessful efforts have been dedicated to the search of therapeutic options to treat the deleterious inflammatory components of sepsis. Recent findings on neuronal networks controlling immunity raised expectations for novel therapeutic strategies to promote the regulation of sterile inflammation, such as autoimmune diseases. Interesting studies have dissected the anatomical constituents of the so-called "cholinergic anti-inflammatory pathway", suggesting that electrical vagus nerve stimulation and pharmacological activation of beta-2 adrenergic and alpha-7 nicotinic receptors could be alternative strategies for improving inflammatory conditions. However, the literature on infectious diseases, such as sepsis, is still controversial and, therefore, the real therapeutic potential of this neuroimmune pathway is not well defined. In this review, we will discuss the beneficial and detrimental effects of neural manipulation in sepsis, which depend on the multiple variables of the immune system and the nature of the infection. These observations suggest future critical studies to validate the clinical implications of vagal parasympathetic signaling in sepsis treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adrenergic receptor; Inflammatory reflex; Nicotinic receptor; Sepsis; Vagus nerve

Mesh:

Substances:

Year:  2016        PMID: 27979692      PMCID: PMC6291365          DOI: 10.1016/j.phrs.2016.12.014

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  82 in total

1.  Septic shock: on the importance of being tolerant.

Authors:  Ruslan Medzhitov
Journal:  Immunity       Date:  2013-11-14       Impact factor: 31.745

Review 2.  Fever and sickness behavior: Friend or foe?

Authors:  L M Harden; S Kent; Q J Pittman; J Roth
Journal:  Brain Behav Immun       Date:  2015-07-15       Impact factor: 7.217

3.  Stimulation of alpha7 nicotinic acetylcholine receptor inhibits CD14 and the toll-like receptor 4 expression in human monocytes.

Authors:  Ryosuke Hamano; Hideo Kohka Takahashi; Hiromi Iwagaki; Tadashi Yoshino; Masahiro Nishibori; Noriaki Tanaka
Journal:  Shock       Date:  2006-10       Impact factor: 3.454

4.  Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis.

Authors:  Jose C Alves-Filho; Andressa Freitas; Fabricio O Souto; Fernando Spiller; Heitor Paula-Neto; Joao S Silva; Ricardo T Gazzinelli; Mauro M Teixeira; Sergio H Ferreira; Fernando Q Cunha
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

5.  Stimulation of acetylcholine receptors impairs host defence during pneumococcal pneumonia.

Authors:  I A J Giebelen; M Leendertse; S Florquin; T van der Poll
Journal:  Eur Respir J       Date:  2008-10-01       Impact factor: 16.671

6.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Authors:  Mounia Azzi; Pascale G Charest; Stéphane Angers; Guy Rousseau; Trudy Kohout; Michel Bouvier; Graciela Piñeyro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

7.  beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock.

Authors:  Taka-Aki Nakada; James A Russell; John H Boyd; Rosalia Aguirre-Hernandez; Katherine R Thain; Simone A Thair; Emiri Nakada; Melissa McConechy; Keith R Walley
Journal:  Am J Respir Crit Care Med       Date:  2009-10-22       Impact factor: 21.405

8.  TLR2, TLR4 and the MYD88 signaling pathway are crucial for neutrophil migration in acute kidney injury induced by sepsis.

Authors:  Angela Castoldi; Tárcio Teodoro Braga; Matheus Correa-Costa; Cristhiane Fávero Aguiar; Ênio José Bassi; Reinaldo Correa-Silva; Rosa Maria Elias; Fábia Salvador; Pedro Manoel Moraes-Vieira; Marcos Antônio Cenedeze; Marlene Antônia Reis; Meire Ioshie Hiyane; Álvaro Pacheco-Silva; Giselle Martins Gonçalves; Niels Olsen Saraiva Câmara
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

9.  Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity.

Authors:  Prodyot K Chatterjee; Michael M Yeboah; Oonagh Dowling; Xiangying Xue; Saul R Powell; Yousef Al-Abed; Christine N Metz
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

10.  Spleen vagal denervation inhibits the production of antibodies to circulating antigens.

Authors:  Ruud M Buijs; Jan van der Vliet; Mari-Laure Garidou; Inge Huitinga; Carolina Escobar
Journal:  PLoS One       Date:  2008-09-05       Impact factor: 3.240

View more
  19 in total

1.  From neuroimunomodulation to bioelectronic treatment of rheumatoid arthritis.

Authors:  Alexandre Kanashiro; Gabriel Shimizu Bassi; Fernando de Queiróz Cunha; Luis Ulloa
Journal:  Bioelectron Med (Lond)       Date:  2018-05

2.  Inhibition of spinal p38 MAPK prevents articular neutrophil infiltration in experimental arthritis via sympathetic activation.

Authors:  Alexandre Kanashiro; Marcelo Franchin; Gabriel Shimizu Bassi; Dênis Augusto Reis Santana; Thiago Mattar Cunha; Fernando Queiróz Cunha; Luis Ulloa; Gerson Jonathan Rodrigues
Journal:  Fundam Clin Pharmacol       Date:  2017-12-22       Impact factor: 2.748

Review 3.  Heart rate variability: Measurement and emerging use in critical care medicine.

Authors:  Brian W Johnston; Richard Barrett-Jolley; Anton Krige; Ingeborg D Welters
Journal:  J Intensive Care Soc       Date:  2019-06-11

4.  Cholinergic leukocytes in sepsis and at the neuroimmune junction in the spleen.

Authors:  Donald B Hoover; Megan D Poston; Stacy Brown; Sarah E Lawson; Cherie E Bond; Anthony M Downs; David L Williams; Tammy R Ozment
Journal:  Int Immunopharmacol       Date:  2020-03-03       Impact factor: 4.932

5.  [Low-intensity pulsed ultrasound pretreatment inhibits HMGB1 expression and attenuates lung ischemia-reperfusion injury in rats via the cholinergic anti-inflammatory pathway].

Authors:  Liangchao Qu; Jinxiu Yan; Zhangjie Jiang; Zhiping Song; Foquan Luo; Qinghua Peng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-08-30

6.  Dopaminergic Control of Inflammation and Glycemia in Sepsis and Diabetes.

Authors:  Eleonora Feketeova; Zhifeng Li; Biju Joseph; Roshan Shah; Zoltan Spolarics; Luis Ulloa
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

7.  Curcumin attenuates high glucose-induced inflammatory injury through the reactive oxygen species-phosphoinositide 3-kinase/protein kinase B-nuclear factor-κB signaling pathway in rat thoracic aorta endothelial cells.

Authors:  Zhen Zhang; Keming Li
Journal:  J Diabetes Investig       Date:  2017-12-12       Impact factor: 4.232

Review 8.  Aptamer-based biosensors for the diagnosis of sepsis.

Authors:  Lubin Liu; Zeyu Han; Fei An; Xuening Gong; Chenguang Zhao; Weiping Zheng; Li Mei; Qihui Zhou
Journal:  J Nanobiotechnology       Date:  2021-07-19       Impact factor: 10.435

9.  The α7-nAChR/heme oxygenase-1/carbon monoxide pathway mediates the nicotine counteraction of renal inflammation and vasoconstrictor hyporeactivity in endotoxic male rats.

Authors:  Abdalla M Wedn; Sahar M El-Gowilly; Mahmoud M El-Mas
Journal:  Inflamm Res       Date:  2020-01-02       Impact factor: 6.986

10.  Association between early serum cholinesterase activity and 30-day mortality in sepsis-3 patients: A retrospective cohort study.

Authors:  Zheng-Liang Peng; Liang-Wei Huang; Jian Yin; Ke-Na Zhang; Kang Xiao; Guo-Zhong Qing
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.